Outcomes of Rivaroxaban and Aspirin in PAD After Endovascular Revascularization
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Assessing the outcomes of using Rivaroxaban plus Aspirin in patients with Lower Extremity
Peripheral Arterial Disease after Endovascular Revascularization